Posted by Michael Wonder on 09 Feb 2021
SMC issues positive decision for treatment with AbbVie’s Rinvoq (upadacitinib) in severe active rheumatoid arthritis
9 February 2021 - Positive indication means upadacitinib will be available to those with previously treated severe active rheumatoid arthritis.
The Scottish Medicines Consortium has issued a positive decision recommending treatment by NHS Scotland with upadacitinib. Upadacitinib is a janus kinase inhibitor which is a once-daily oral therapy, for people with previously treated severe active rheumatoid arthritis.
